CVS is parting ways with its troubled long-term care pharmacy subsidiary, Omnicare, eight months after it filed for bankruptcy.

The retail pharmacy giant announced in mid-May that a bankruptcy court had approved Omnicare’s sale to GenieRx, a joint partnership between private investment firm Milrose Capital and Integro Asset Management, a healthcare investment and management firm. The deal is valued around $250 million, according to court filings, and is expected to close later this year.

In September 2025, CVS announced Omnicare had filed for Chapter 11 bankruptcy after a federal judge ordered the subsidiary to pay almost $1 billion in penalties for allegedly overcharging Medicare, Medicaid, and military insurer Tricare for prescriptions.

David Azzolina, Omnicare’s president, said in a statement shared with Healthcare Brew that “supporting our customers and residents is our top priority” through the sale process and that the company is “fully committed to providing optimal care for the residents and customers we serve.”

Rowan Farber, CEO of Integro Healthcare Services, said in a press release that “GenieRx’s investment in Omnicare is a testament to the strength of their platform” and that it “share[s] a commitment to delivering reliable service, clinical expertise, and continuity of care to the patients and communities who depend on it most.”

Despite Omnicare’s struggles, CVS is still seeing growth.—MA

Welcome to Recall Roundup, our monthly must-read for anyone who ever uses or purchases medical devices.

FDA recalls occur when a device is defective or poses a potential health risk. The FDA ranks them in severity from Class III (the least dangerous) to Class I, meaning the defect has a decent chance of seriously injuring or killing a patient.

Without further ado, here’s our roundup of May’s Class I recalls.

Cracked catheters. In an April 2 letter to customers, Cook Medical recalled several lots of sizing catheters—single-use catheters with gold marker bands—because they’re at an increased risk of cracking or breaking. Customers are being asked to return affected products to Cook.

See the full list here.—CC

Eli Lilly may be winning the GLP-1 battle, but it’s turning its attention back to the broader pharmaceutical war.

On May 26, the pharma giant announced it agreed to acquire three vaccine makers for roughly $4 billion in total:

• Curevo is creating a shingles vaccine with fewer side effects than similar shots on the market. Eli Lilly is buying the company for up to $1.5 billion.
• LimmaTech is working to develop vaccines for bacterial pathogens, including some STIs. Eli Lilly agreed to pay $780 million for the biotech company.
• The Vaccine Company (B- for name creativity) is developing a vaccine to protect against the Epstein-Barr virus. Eli Lilly is paying $1.55 billion for the firm.

Keep reading on Brew Markets.—LB